| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yilin Tang, Yuting Li, Peiyu Cao, Yingbo Dong, Guoxin Xu, Qi Si, Runda Li, Yuxiu Su. Striatum and globus pallidus structural abnormalities in schizophrenia: A retrospective study of the different stages of the disease. Progress in neuro-psychopharmacology & biological psychiatry. 2024-05-01. PMID:38692473. |
the basal ganglia are important structures for the release of dopamine in the limbic circuits of the midbrain, and the striatum and globus pallidus are the major nuclei of the basal ganglia, and the dysfunction of these regions has been the basis of many models that have attempted to explain the underlying mechanisms of schizophrenia symptoms. |
2024-05-01 |
2024-05-04 |
Not clear |
| Leonardo Sportelli, Daniel P Eisenberg, Roberta Passiatore, Enrico D'Ambrosio, Linda A Antonucci, Jasmine S Bettina, Qiang Chen, Aaron L Goldman, Michael D Gregory, Kira Griffiths, Thomas M Hyde, Joel E Kleinman, Antonio F Pardiñas, Madhur Parihar, Teresa Popolizio, Antonio Rampino, Joo Heon Shin, Mattia Veronese, William S Ulrich, Caroline F Zink, Alessandro Bertolino, Oliver D Howes, Karen F Berman, Daniel R Weinberger, Giulio Pergol. Dopamine signaling enriched striatal gene set predicts striatal dopamine synthesis and physiological activity in vivo. Nature communications. vol 15. issue 1. 2024-04-30. PMID:38688917. |
a higher polygenic risk score for schizophrenia parsed by this set of genes predicts greater dopamine synthesis in the striatum and greater striatal activation during reward anticipation. |
2024-04-30 |
2024-05-03 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
it is mainly used to treat schizophrenia in adults through its antagonistic action on dopamine and 5-hydroxytryptamine receptors. |
2024-04-29 |
2024-05-01 |
Not clear |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
the review discusses aspects of the use of atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia using the model of aripiprazole, a partial agonist of dopamine receptors. |
2024-04-27 |
2024-04-30 |
Not clear |
| Paulina Dudzik, Klaudia Lustyk, Karolina Pytk. Beyond dopamine: Novel strategies for schizophrenia treatment. Medicinal research reviews. 2024-04-23. PMID:38653551. |
beyond dopamine: novel strategies for schizophrenia treatment. |
2024-04-23 |
2024-04-26 |
Not clear |
| Hannah B Elam, Stephanie M Perez, Jennifer J Donegan, Nicole E Eassa, Daniel J Lodg. Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats. Schizophrenia research. vol 267. 2024-03-26. PMID:38531158. |
in utero lhx6 knockdown resulted in increased ventral tegmental area (vta) dopamine neuron population activity and a sex-specific increase in locomotor response to a psychotomimetic, consistent with positive symptomology of schizophrenia. |
2024-03-26 |
2024-03-29 |
human |
| Aineng Peng, Jianbo Chai, Haiyuan Wu, Bing Bai, Huihui Yang, Weizhi He, Yonghou Zha. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists. Neuropsychiatric disease and treatment. vol 20. 2024-03-25. PMID:38525480. |
new therapeutic targets and drugs for schizophrenia beyond dopamine d2 receptor antagonists. |
2024-03-25 |
2024-03-27 |
Not clear |
| Aineng Peng, Jianbo Chai, Haiyuan Wu, Bing Bai, Huihui Yang, Weizhi He, Yonghou Zha. New Therapeutic Targets and Drugs for Schizophrenia Beyond Dopamine D2 Receptor Antagonists. Neuropsychiatric disease and treatment. vol 20. 2024-03-25. PMID:38525480. |
research on alternative targets for antipsychotic drugs, beyond the dopamine d2 receptor, has expanded the potential treatment options for schizophrenia and gives an important way to address the challenge of refractory schizophrenia. |
2024-03-25 |
2024-03-27 |
Not clear |
| Masanobu Kogure, Nobuhisa Kanahara, Atsuhiro Miyazawa, Yuki Shiko, Ikuo Otsuka, Koichi Matsuyama, Masayuki Takase, Makoto Kimura, Hiroshi Kimura, Kiyomitsu Ota, Keita Idemoto, Masaki Tamura, Yasunori Oda, Taisuke Yoshida, Satoshi Okazaki, Fumiaki Yamasaki, Yusuke Nakata, Yoshinori Watanabe, Tomihisa Niitsu, Akitoyo Hishimoto, Masaomi Iy. Association of Frontiers in psychiatry. vol 14. 2024-03-13. PMID:38476817. |
however, evidence from multiple studies suggests that patients with schizophrenia who respond well to antipsychotic medication have a higher dopamine (da) state in brain synaptic clefts whereas patients with trs do not show enhanced da synthesis/release pathways. |
2024-03-13 |
2024-03-15 |
Not clear |
| Bhakti Khanolkar, Pravin Shend. BSA nanoclusters-based sensor for detection of dopamine in schizophrenia from biofluids. Drug development and industrial pharmacy. 2024-03-12. PMID:38470160. |
bsa nanoclusters-based sensor for detection of dopamine in schizophrenia from biofluids. |
2024-03-12 |
2024-03-14 |
Not clear |
| Sophie R Debs, Illya Conn, Brendan Navaneethan, Andriane G Penklis, Urs Meyer, Simon Killcross, Cynthia Shannon Weickert, Tertia D Purves-Tyso. Maternal immune activation and estrogen receptor modulation induce sex-specific dopamine-related behavioural and molecular alterations in adult rat offspring. Brain, behavior, and immunity. 2024-03-02. PMID:38431238. |
dopamine dysregulation contributes to psychosis and cognitive deficits in schizophrenia that can be modelled in rodents by inducing maternal immune activation (mia). |
2024-03-02 |
2024-03-06 |
rat |
| Samantha Alvarez-Herrera, Mauricio Rosel Vales, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Yvonne Flores-Medina, José Luis Maldonado-García, Ricardo Saracco-Alvarez, Raúl Escamilla, Lenin Pavó. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399382. |
risperidone decreases expression of serotonin receptor-2a (5-ht2a) and serotonin transporter (sert) but not dopamine receptors and dopamine transporter (dat) in pbmcs from patients with schizophrenia. |
2024-02-24 |
2024-02-26 |
Not clear |
| Samantha Alvarez-Herrera, Mauricio Rosel Vales, Gilberto Pérez-Sánchez, Enrique Becerril-Villanueva, Yvonne Flores-Medina, José Luis Maldonado-García, Ricardo Saracco-Alvarez, Raúl Escamilla, Lenin Pavó. Risperidone Decreases Expression of Serotonin Receptor-2A (5-HT2A) and Serotonin Transporter (SERT) but Not Dopamine Receptors and Dopamine Transporter (DAT) in PBMCs from Patients with Schizophrenia. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399382. |
dopamine and serotonin receptors and transporters play an essential role in the pathophysiology of schizophrenia; changes in their expression have been reported in neurons and leukocytes. |
2024-02-24 |
2024-02-26 |
Not clear |
| Xenia M Hart, Yasue Mitsukura, Robert R Bies, Hiroyuki Uchid. Unraveling the Influence of Age, IQ, Education, and Negative Symptoms on Neurocognitive Performance in Schizophrenia: A Conditional Inference Tree Analysis. Pharmacopsychiatry. 2024-02-22. PMID:38387603. |
the complex nature of neurocognitive impairment in schizophrenia has been discussed in light of the mixed effects of antipsychotic drugs, psychotic symptoms, dopamine d |
2024-02-22 |
2024-02-25 |
Not clear |
| Konstantinos N Fountoulakis, Eva Maria Tsapaki. Neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. Molecular psychiatry. 2024-02-20. PMID:38374355. |
neither serotonin disorder is at the core of depression nor dopamine at the core of schizophrenia; still these are biologically based mental disorders. |
2024-02-20 |
2024-02-22 |
Not clear |
| Zijin Feng, Zhijing Hu, Lei Li, Minquan Yu, Yiting Zhang, Peng Jing, Xiangqing Xu, Jinhui Wu, Yiqiao Hu, Xiangyang X. Assessing NH300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia. Frontiers in pharmacology. vol 15. 2024-02-08. PMID:38327987. |
assessing nh300094, a novel dopamine and serotonin receptor modulator with cognitive enhancement property for treating schizophrenia. |
2024-02-08 |
2024-02-10 |
Not clear |
| Qiongqiong Wu, Yujun Long, Xingjie Peng, Chuhan Song, Jingmei Xiao, Xiaoyi Wang, Furu Liu, Peng Xie, Jinqing Yang, Zhe Shi, Zhonghua Hu, Colin McCaig, David St Clair, Bing Lang, Renrong W. Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia. Translational psychiatry. vol 14. issue 1. 2024-02-06. PMID:38320995. |
prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia. |
2024-02-06 |
2024-02-09 |
mouse |
| Qiongqiong Wu, Yujun Long, Xingjie Peng, Chuhan Song, Jingmei Xiao, Xiaoyi Wang, Furu Liu, Peng Xie, Jinqing Yang, Zhe Shi, Zhonghua Hu, Colin McCaig, David St Clair, Bing Lang, Renrong W. Prefrontal cortical dopamine deficit may cause impaired glucose metabolism in schizophrenia. Translational psychiatry. vol 14. issue 1. 2024-02-06. PMID:38320995. |
these findings led us to hypothesize that the prefrontal cortical dopamine deficit, which is known to be associated with negative symptoms, may be responsible for abnormal glucose metabolism in schizophrenia. |
2024-02-06 |
2024-02-09 |
mouse |
| Simon Anhøj, Bjørn Ebdrup, Mette Ødegaard Nielsen, Patrick Antonsen, Birte Glenthøj, Egill Rostru. Functional Connectivity Between Auditory and Medial Temporal Lobe Networks in Antipsychotic-Naïve Patients With First-Episode Schizophrenia Predicts the Effects of Dopamine Antagonism on Auditory Verbal Hallucinations. Biological psychiatry global open science. vol 4. issue 1. 2024-02-01. PMID:38298804. |
functional connectivity between auditory and medial temporal lobe networks in antipsychotic-naïve patients with first-episode schizophrenia predicts the effects of dopamine antagonism on auditory verbal hallucinations. |
2024-02-01 |
2024-02-03 |
Not clear |
| Xingyue Zeng, ChengYan Wu, Yongkai Cao, Huijun Li, Xiaohan Zhan. Mdm2-mediated ubiquitination of PKCβII is responsible for insulin-induced heterologous desensitization of dopamine D FEBS letters. 2024-02-01. PMID:38302840. |
mdm2-mediated ubiquitination of pkcβii is responsible for insulin-induced heterologous desensitization of dopamine d the insulin and dopaminergic systems in the brain are associated with schizophrenia and parkinson's disease with respect to etiology and treatment. |
2024-02-01 |
2024-02-04 |
Not clear |